Description
PGI2 is an unstable COX metabolite detected first in vascular endothelial cells.{502,443,933} It elevates platelet cAMP and is a potent vasodilator and inhibitor of human platelet aggregation with an IC50 value of 5 nM.{4375} PGI2 is stable in basic buffers (pH=8), but it is rapidly hydrolyzed to 6-keto PGF1α in neutral or acidic solutions. The half-life is short both in vivo and in vitro, ranging from 30 seconds to a few minutes. PGI2 is administered by continuous infusion in humans for the treatment of idiopathic pulmonary hypertension.{5466}
Formal name: 6,9α-epoxy-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid, monosodium salt
Synonyms: Epoprostenol|PGI2|Prostacyclin
Molecular weight: 374.5
CAS: 61849-14-7
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Lipids|Prostaglandins||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Vasculature|Vasodilation||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway